CAMBRIDGE, MA — Researchers at the Massachusetts Institute of Technology have identified a gene mutation that could explain why individuals with schizophrenia struggle to incorporate new information and make decisions. This discovery, centered on a specific brain circuit, offers new hope for targeted treatments.
In a groundbreaking study published in Nature Neuroscience, MIT neuroscientists revealed that a mutation in the gene grin2a impairs a brain circuit crucial for updating beliefs based on new information. This finding could pave the way for novel therapies aimed at alleviating cognitive impairments in schizophrenia patients.
Understanding the Genetic Link
Schizophrenia, a complex mental disorder, has long been known to have a genetic component. While the general population faces a 1% risk of developing the condition, this risk increases significantly for those with a family history of the disease. Identifying the genetic underpinnings has been a major focus for scientists worldwide.
Researchers at the Stanley Center for Psychiatric Research at the Broad Institute have previously identified over 100 gene variants associated with schizophrenia. However, many of these variants reside in non-coding regions, complicating efforts to understand their impact on disease development.
“We are quite confident this circuit is one of the mechanisms that contributes to the cognitive impairment that is a major part of the pathology of schizophrenia,” said Guoping Feng, a leading researcher in the study.
The Role of the grin2a Gene
Using whole-exome sequencing, a technique that focuses on the protein-coding regions of the genome, researchers identified mutations in 10 genes that significantly increase schizophrenia risk. Among these, the grin2a gene encodes a protein component of the NMDA receptor, crucial for synaptic plasticity and cognitive function.
To explore the effects of this mutation, Feng and his team developed a mouse model with the grin2a mutation. The study’s lead authors, Tingting Zhou and Yi-Yun Ho, observed that these mice exhibited behaviors analogous to the cognitive symptoms seen in schizophrenia patients.
Experimenting with Decision-Making
The researchers designed an experiment to test the mice’s ability to adapt to changing reward scenarios. Mice had to choose between two levers: one offering a consistent low reward and another offering a high reward that required increasing effort over time.
Healthy mice adapted their choices based on changing conditions, but those with the grin2a mutation struggled to adjust, mirroring the decision-making difficulties faced by schizophrenia patients.
“Neurotypical animals make adaptive decisions in this changing environment,” Zhou explained. “For animals with the mutation, the switch happens much later. Their adaptive decision-making is much slower compared to the wild-type animals.”
Implications for Future Treatments
The study identified the mediodorsal thalamus, a brain region affected by the grin2a mutation, as a key player in this impaired decision-making process. This region, part of a thalamocortical circuit, is essential for cognitive functions such as executive control and decision-making.
Using advanced techniques like optogenetics, the researchers demonstrated that activating neurons in the mediodorsal thalamus could reverse the behavioral symptoms in mice with the mutation. This suggests potential therapeutic targets within this circuit for schizophrenia patients.
According to the researchers, “Targeting this circuit could offer a way to overcome some of the cognitive impairments seen in schizophrenia patients.”
Looking Ahead
While only a small percentage of schizophrenia patients carry the grin2a mutation, the study suggests that dysfunction in this brain circuit could be a common mechanism underlying cognitive impairments in the disorder. The findings encourage further research into drug development targeting this circuit.
As the scientific community continues to unravel the complexities of schizophrenia, this study represents a significant step toward understanding the genetic and neural bases of the disorder. The hope is that these insights will lead to more effective treatments, improving the quality of life for those affected by schizophrenia.
